yingweiwo

PD 174265

Alias: PD-174265; PD174265; pd 174265; 216163-53-0; N-{4-[(3-Bromophenyl)amino]quinazolin-6-Yl}propanamide; 4-[(3-Bromophenyl)amino]-6-propionylamidoquinazoline; 4-aminoquinazoline, 2a; PD-174265; CHEMBL188762; N-(4-((3-Bromophenyl)amino)quinazolin-6-yl)propionamide; PD 174265
Cat No.:V27176 Purity: ≥98%
PD 174265 is a potent, cell-penetrating/penetrable, reversible, and selective EGFR inhibitor (antagonist) with IC50 of 450 pM.
PD 174265
PD 174265 Chemical Structure CAS No.: 216163-53-0
Product category: New1
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
10mg
50mg
100mg
250mg
Other Sizes
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text

 

  • Business Relationship with 5000+ Clients Globally
  • Major Universities, Research Institutions, Biotech & Pharma
  • Citations by Top Journals: Nature, Cell, Science, etc.
Top Publications Citing lnvivochem Products
Product Description
PD 174265 is a potent, cell-penetrating/penetrable, reversible, and selective EGFR inhibitor (antagonist) with IC50 of 450 pM.
Biological Activity I Assay Protocols (From Reference)
Targets
EGFR (IC50 = 0.45 nM)
ln Vitro
When the protein was incubated with PD174265, no increase in mass occurred, indicating the lack of a covalent modification. Trypsin digestion of the drug-bound protein and analyses by liquid chromatography-ESI tandem MS (MS/MS) identified Cys-773 as the predominant site of interaction (Fig. 3b). The only other modified residue detected was Cys-926; however, this represented a relatively minor component. No other residues, including the four remaining cysteines, were found to be altered. As additional evidence that Cys-773 is the specific amino acid that combines with PD 168393, recombinant wild-type full cytoplasmic domain of human EGFr and a point mutant, in which Cys-773 was replaced with Ser (C773S), were expressed in baculovirus and purified from infected insect cells. Both wild-type and mutant protein exhibited comparable TK activity and were inhibited by both PD 168393 and PD174265 at similar doses[1].
ln Vivo
To illustrate the advantage of irreversibility, a direct comparison between PD 168393 (irreversible) and PD174265 (reversible) for target modulation in viable cells is shown in Table 2. PD 168393 inhibited EGFr autophosphorylation in A431 human epidermoid carcinoma cells with >9-fold greater potency than PD174265. An even greater difference was seen against heregulin-mediated tyrosine phosphorylation in MDA-MB-453 human breast carcinoma cells, where PD 168393 was >30-fold more potent. The therapeutic advantage of irreversible inhibition is illustrated quite dramatically in Fig. 6a, which shows a head-to-head comparison of in vivo activity for PD 168393 and PD174265 against the A431 human epidermoid carcinoma grown as a xenograft in nude mice. PD 168393 was far superior to PD174265 in maintaining suppression of tumor growth with once-daily i.p. dosing. PD 168393 produced tumor growth inhibition of 115%, which for this experiment is defined as the median time for treated tumors to reach three volume doublings minus the median time for control tumors to reach three volume doublings, expressed as a percent of treatment duration (15 days). PD174265, in contrast, produced a tumor growth inhibition of only 13%. The antitumor activity of these two compounds correlated with their ability to suppress the phosphotyrosine content of the EGFr. Both compounds had reduced the phosphorylation status by ≈80%, 4 hr after injection (Fig. 6b). However, by 8 hr, phosphorylation had returned to 75% of controls in mice treated with the reversible compound, PD174265, and to 100% after 24 hr. In contrast, the phosphotyrosine content of EGFr in animals receiving PD 168393 was still reduced by 50% 24 hr after injection. The therapeutic advantage of PD 168393 was maintained despite a lower plasma concentration than that of PD174265 at all time points examined (data not shown)[1].
Enzyme Assay
A solution of PD 168393 or PD174265 (in dimethyl sulfoxide) was added to 50 μg of EGFr TK catalytic domain in 20 mM Tris (pH 8.0), 150 mM NaCl, 1 mM DTT, 1 mM EDTA, and 1 μg/ml of the protease inhibitors (aprotinin and leupeptin), and diluted with 75 mM ammonium bicarbonate (pH 7.5). After 90 min, the reaction was quenched by addition of 5% (vol/vol) acetic acid. An aliquot of protein was analyzed by electrospray ionization (ESI)-MS on a Finnigan MAT 900Q mass spectrometer, equipped with a low-flow micro-ESI source operating at 150 nl/min. The remaining protein was reduced, alkylated, and digested with 0.5 μg of trypsin as described (40). Lyophilized tryptic peptides were suspended in 0.1% trifluoroacetic acid/2% CH3CN and analyzed by liquid chromatography-ESI-MS on a Michrom BioResources Magic 2002 HPLC equipped with a 0.3 × 15 mm Vydac C18 column and coupled to a Finnigan LCQ quadruple ion trap mass spectrometer. Data were collected using the Finnigan navigator 1.0.1 data acquisition software set to the following default values for the automatic gain control for full scan MS, zoom scan MS, and MS/MS, respectively: 5 × 107, 1 × 107, and 2 × 107. A maximum injection time of 200 ms and three microscans were used to collect data in all modes. A relative collision energy of 35% was used for MS/MS fragmentation spectra.
References

[1]. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):12022-7.

Additional Infomation
A class of high-affinity inhibitors is disclosed that selectively target and irreversibly inactivate the epidermal growth factor receptor tyrosine kinase through specific, covalent modification of a cysteine residue present in the ATP binding pocket. A series of experiments employing MS, molecular modeling, site-directed mutagenesis, and 14C-labeling studies in viable cells unequivocally demonstrate that these compounds selectively bind to the catalytic domain of the epidermal growth factor receptor with a 1:1 stoichiometry and alkylate Cys-773. While the compounds are essentially nonreactive in solution, they are subject to rapid nucleophilic attack by this particular amino acid when bound in the ATP pocket. The molecular orientation and positioning of the acrylamide group in these inhibitors in relation to Cys-773 entirely support these results as determined from docking experiments in a homology-built molecular model of the ATP site. Evidence is also presented to indicate that the compounds interact in an analogous fashion with erbB2 but have no activity against the other receptor tyrosine kinases or intracellular tyrosine kinases that were tested in this study. Finally, a direct comparison between 6-acrylamido-4-anilinoquinazoline and an equally potent but reversible analog shows that the irreversible inhibitor has far superior in vivo antitumor activity in a human epidermoid carcinoma xenograft model with no overt toxicity at therapeutically active doses. The activity profile for this compound is prototypical of a generation of tyrosine kinase inhibitors with great promise for therapeutic significance in the treatment of proliferative disease.[1]
The irreversible nature of these compounds may offer other potential advantages in terms of target suppression and in vivo pharmacokinetics. Prolonged suppression of the kinase target(s) will likely be necessary for maximum antitumor activity, and an irreversible inhibitor will provide an advantage in this respect by permanently eliminating existing kinase activity, which will return only when new receptor is synthesized. The present compounds would require that plasma concentrations be attained only long enough to briefly expose the receptors to drug, which would irreversibly suppress their kinase activity. Plasma levels could then rapidly decline while kinase activity would remain inactivated. This has the potential advantage of lowering the minimal plasma concentration at which activity occurs, minimizing multiple dosing requirements and eliminating the requirement for long plasma half-lives without compromising efficacy. All of these considerations could reduce toxicity due to any nonspecific interactions that may occur at high or prolonged plasma levels. These pharmacokinetic factors may be contributing in part to the data in Fig. 6, where it is clear that under the dosing schedule given in this experiment, PD 168393 was markedly superior to the reversible compound, PD 174265.[1]
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C17H15BRN4O
Molecular Weight
371.24
Exact Mass
370.043
Elemental Analysis
C, 55.00; H, 4.07; Br, 21.52; N, 15.09; O, 4.31
CAS #
216163-53-0
PubChem CID
4709
Appearance
Light yellow to yellow solid powder
LogP
4.63
Hydrogen Bond Donor Count
2
Hydrogen Bond Acceptor Count
4
Rotatable Bond Count
4
Heavy Atom Count
23
Complexity
408
Defined Atom Stereocenter Count
0
InChi Key
WUPUZEMRHDROEO-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H15BrN4O/c1-2-16(23)21-13-6-7-15-14(9-13)17(20-10-19-15)22-12-5-3-4-11(18)8-12/h3-10H,2H2,1H3,(H,21,23)(H,19,20,22)
Chemical Name
N-[4-(3-bromoanilino)quinazolin-6-yl]propanamide
Synonyms
PD-174265; PD174265; pd 174265; 216163-53-0; N-{4-[(3-Bromophenyl)amino]quinazolin-6-Yl}propanamide; 4-[(3-Bromophenyl)amino]-6-propionylamidoquinazoline; 4-aminoquinazoline, 2a; PD-174265; CHEMBL188762; N-(4-((3-Bromophenyl)amino)quinazolin-6-yl)propionamide; PD 174265
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Note: This product requires protection from light (avoid light exposure) during transportation and storage.
Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO : ~125 mg/mL (~336.72 mM)
Solubility (In Vivo)
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution 50 μL Tween 80 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO 400 μLPEG300 50 μL Tween 80 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO 100 μLPEG300 200 μL castor oil 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH 400 μLPEG300 50 μL Tween 80 450 μL Saline)


Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders


Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.6937 mL 13.4684 mL 26.9368 mL
5 mM 0.5387 mL 2.6937 mL 5.3874 mL
10 mM 0.2694 mL 1.3468 mL 2.6937 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Contact Us